Targets › HPV31
5 programs from 5 companies in 10 trials: 9 Phase 3, 1 Phase 4; Infectious disease, Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on HPV31, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Miquel Angel Pavon Ribas | Nonavalent HPV vaccine (9vHPV/Gardasil-9™) Virus-like particles (VLPs) of HPV major capsid L1 protein from 9 HPV types that generate | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 4 | Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) | Dec 2026 |
| Merck & Co. (MSD) | 9-valent human papillomavirus (9vHPV) vaccine (Types 6, 11, 16, 18, 31, 33, 45, Aluminum-adjuvanted recombinant protein vaccine containing virus-like particles of recombi | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Papillomavirus Infections; Genital Warts | Jan 2027 |
| Shanghai Bovax Biotechnology | 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recom 9-valent HPV recombinant vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Genital Wart; Cervical Cancer | Jul 2027 |
| Xiamen University | Nonavalent HPV vaccine (6,11,16,18,31,33,45,52,58 Type) Recombinant human papillomavirus vaccine targeting 9 HPV types | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Cervical Intraepithelial Neoplasia | Dec 2027 |
| Beijing Health Guard Biotechnology | Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (H Recombinant nonavalent HPV vaccine targeting 9 HPV types | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Human Papillomavirus Infection | Mar 2028 |
Papillomavirus Infections (4) Genital Warts (1) Cervical Intraepithelial Neoplasia (1) Human Papillomavirus Infection (1) Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) (1) Genital Wart (1) Cervical Cancer (1)
other (3), mixed (2)
Merck & Co. (MSD) (1) Xiamen University (1) Beijing Health Guard Biotechnology (1) Miquel Angel Pavon Ribas (1) Shanghai Bovax Biotechnology (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.